lintuzumab/rGel (Targa Therapeutics)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug Namelintuzumab/rGel (Targa Therapeutics)
Drug Alias NameHuM195-gelonin immunotoxin (Targa Therapeutics)HuM195/rGel (Targa Therapeutics)HuM195/rGel (Targa Therapeutics)HuM195/rGel (MD Anderson)conjugated anti-CD33 antibodies (MD Anderson) +[8] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugateBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody conjugate
Mechanisms of ActionMyeloid cell surface antigen CD33 inhibitors
TargetsMyeloid cell surface antigen CD33
Therapy Area/IndicationsLeukemia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesMemorial Sloan Kettering Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesTarga Therapeutics CorpMemorial Sloan Kettering Cancer CenterThe University Of Texas MD Anderson Cancer Center
Active IndicationsN/A
Inactive IndicationsLeukemia

Other Information

ATC CodeN/A
Related LinksN/A